Tirzepatide reaches patients three ways, and confusing them is the most common mistake people make when they start looking. Zepbound is the FDA-approved product for weight management. Mounjaro is the FDA-approved product for type 2 diabetes. Compounded tirzepatide is a preparation made by a licensed pharmacy for an individual patient, and it is not FDA-approved. All three require a prescription from a clinician licensed in your state. None of them is a version of the others.
Which route is right depends less on price than on which one you are actually eligible for, so start there.
Zepbound: the approved weight-management product
Zepbound’s prescribing information indicates it, alongside a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction in adults with obesity, or adults with overweight who also have at least one weight-related condition. It carries a second indication for moderate to severe obstructive sleep apnea in adults with obesity. Its safety and effectiveness in children have not been established.
The indications use the words obesity and overweight rather than printing numbers; the figures people quote come from clinical practice and from the trial populations, not from that section. For assessing an adult, the common starting framework is a body mass index of 30 or above, or 27 or above with a weight-related condition (NIDDK). That is a treatment-screening framework for adults, not a definition of the categories, and NIDDK puts overweight itself at a BMI between 25 and 30.
Dosing starts at 2.5 mg once weekly for four weeks, then increases in 2.5 mg steps no sooner than every four weeks, with maintenance at 5, 10 or 15 mg weekly for weight reduction. That titration matters commercially as well as clinically, because most people do not stay at the starting dose and the price often changes as the dose does.
Like the other drugs in this class, Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2, and for anyone with a serious hypersensitivity to tirzepatide or the product’s other ingredients. It carries a boxed warning about thyroid C-cell tumours seen in rats.
Mounjaro: the approved diabetes product
Mounjaro contains the same molecule, and its label indicates it as an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 and older with type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes at high risk of those events. It is not indicated for chronic weight management. Its adult maximum is 15 mg weekly; for children aged 10 and older the label caps the dose at 10 mg.
This is worth stating plainly because a great deal of internet advice treats Mounjaro and Zepbound as the cheap and expensive versions of one thing. They are two approved products with two different indications. Asking a clinician for Mounjaro to lose weight is asking for an off-label prescription, which is a decision for the prescriber and often a problem for coverage.
What each one costs if you are paying yourself
Checked on September 17, 2026, Lilly’s savings page lists Zepbound self-pay prices for the single-patient-use KwikPen: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5, 10, 12.5 and 15 mg. Each of those is a 28-day supply of up to one KwikPen, not a calendar month, which matters if you are comparing against a monthly subscription price.
The terms on the higher doses are worth reading precisely. The $449 offer applies automatically to an eligible patient’s first purchase of a 7.5, 10, 12.5 or 15 mg KwikPen. Keeping it requires completing the next refill purchase within 45 days of the previous delivery. Lapse that window and regular prices apply: $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg. A refill window is not a discount, it is a condition.
Eligible patients with commercial insurance that covers Zepbound can pay as little as $25 with the savings card, subject to an annual cap, and people on government-funded health programmes are excluded from it. Eligible Medicare Part D patients have a separate route, the Medicare GLP-1 Bridge, at no more than $50 a month; under that programme Zepbound is covered as the KwikPen only, not single-dose vials or pens, and its own clinical eligibility rules apply (Medicare).
The compounded route, and how narrow it now is
Compounded tirzepatide is prepared by a licensed pharmacy against an individual prescription. It is not a generic, not an approved product, and not backed by the brand’s clinical trials. Whatever Zepbound’s trial results showed is evidence about Zepbound.
The legal basis also changed. While tirzepatide was on the FDA’s drug shortage list, that listing opened a route for compounding it. The FDA declared the shortage resolved and the grace periods ran out in 2025. For the state-licensed 503A pharmacies that prepare medication for an individual patient, what remains is narrower: it turns on a prescriber determining that a change made for a specific patient produces a significant difference for that patient, documented on the prescription. That determination is one condition among the requirements that apply to compounding, not a standalone exemption from the rest. Outsourcing facilities registered under the separate 503B section work under different conditions again, so a statement about one route does not describe the other. What was never accurate, then or now, is describing a compounded preparation as simply a cheaper Zepbound.
The FDA has also been active about how this is marketed. Its advisory for telehealth companies promoting compounded drugs sets out the claims it treats as false or misleading: branding that implies the telehealth company is the compounder, describing a compounded drug as a generic version of or the same as an FDA-approved drug, claiming it has been FDA-approved or evaluated for safety and effectiveness, describing it as clinically proven to produce the same result as the approved drug, and claiming it is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. That list is a useful filter when you compare providers: it is a checklist of things a marketing page should not be telling you. The background to the enforcement wave is at the 2026 telehealth enforcement wave.
Where we fit
Gentle Health prescribes compounded tirzepatide where a physician licensed in your state evaluates you and decides it is appropriate. Our pricing is published by dose tier rather than as a starting number: $169 a month at 2.5 to 5 mg weekly, $219 above 5 through 10 mg, and $269 above 10 through 15 mg, with medication, physician care, visits, messaging and refrigerated shipping included. The full breakdown, alongside the brand and direct-purchase comparisons, is at how much does tirzepatide cost per month.
If you have coverage for the approved product, use it. If you do not, compare the direct-purchase price against a compounded programme on the whole cost at the dose you expect to reach, not the introductory tier, and read Why Do GLP-1 Prices Vary So Much? before you assume the cheapest advertised number is the real one.
Frequently asked questions
Is Mounjaro the same as Zepbound? They contain the same active ingredient but are approved for different uses: Zepbound for weight management and obstructive sleep apnea, Mounjaro for type 2 diabetes. Using one for the other’s purpose is an off-label decision for your prescriber.
Do I need a prescription for compounded tirzepatide? Yes. Tirzepatide is a prescription drug in every form, so being treated with a compounded preparation requires a valid prescription written for you by a clinician licensed in your state. More on how that works is in the GLP-1 question library.
Is tirzepatide available in my state? We prescribe it in the states where our physician is licensed, and each has its own page with the licensing details on our states page.
Dr. James Simmons, MD